In a multicenter randomized clinical trial by Luyt et al1 published in this issue of JAMA Internal Medicine, twice-weekly screening for oropharyngeal reactivation of herpes simplex virus (HSV) followed by preemptive treatment with acyclovir during 14 days did not increase the number of ventilator-free days at day 60 in patients who received mechanical ventilation in the intensive care unit (ICU). The study informs a debate that has been ongoing for decades regarding the clinical relevance of HSV reactivation in patients without an apparent prior immunocompromised condition.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Ong DSY, Cremer OL, Bonten MJM. Preemptive Treatment of Herpes Simplex Virus Reactivation in Critically Ill Patients?—Not Based on Current Data. JAMA Intern Med. 2020;180(2):272–273. doi:10.1001/jamainternmed.2019.6423
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: